通过自动化纤维化评分计算和电子提醒消息在2型糖尿病患者中检测晚期肝病的临床照护路径:一项随机对照试验
这项在五个普通内科或糖尿病门诊开展的实用随机对照试验,将2型糖尿病患者按1:1随机分为干预组(基于常规血检自动计算FIB-4和APRI,异常时向临床医生发送电子提醒)和常规照护对照组。干预组纤维化评分升高患者中33.3%接受了适当照护,对照组为3.1%(差异30.2%,95%CI 22.4%至38%,p<0.001)。干预组确诊晚期肝病比例高于对照组(2.1% vs 0.2%,差异1.9%,95%CI 0.61%至3.5%,p=0.006)。
要点
- 自动计算FIB-4和APRI并发送电子提醒可提高纤维化评分异常者的适当照护比例。
- 干预组适当照护率33.3%,对照组3.1%,差异30.2%(95%CI 22.4%至38%,p<0.001)。
- 干预组晚期肝病确诊率2.1%,对照组0.2%,差异1.9%(95%CI 0.61%至3.5%,p=0.006)。
核心结论
- 在非肝病诊疗场所,自动化纤维化评分计算和电子提醒可增加2型糖尿病且纤维化评分异常患者的转诊。
研究设计与样本
- 实用随机对照试验,在香港和马来西亚五个普通内科或糖尿病门诊开展,按1:1随机分组。
- 干预组基于常规血检自动计算FIB-4和APRI,异常结果通过电子提醒消息告知临床医生;对照组接受常规照护。
- 2020年5月至2021年10月筛查1379例患者,干预组533例、对照组528例被分配。
主要发现
- 干预组纤维化评分升高的165例中55例(33.3%)接受了适当照护,对照组131例中4例(3.1%)接受了适当照护;差异30.2%(95%CI 22.4%至38%),p<0.001。
- 干预组533例中11例(2.1%)确诊晚期肝病,对照组528例中1例(0.2%)确诊晚期肝病;差异1.9%(95%CI 0.61%至3.5%),p=0.006。
关键数值与推荐
- 主要结局为纤维化评分升高的患者中1年内接受适当照护(转诊肝病专科或进行特定纤维化评估)的比例。
- 适当照护:干预组165例中55例(33.3%),对照组131例中4例(3.1%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to test the hypothesis that automated fibrosis score calculation and electronic reminder messages could increase the detection of advanced liver disease in patients with type 2 diabetes. DESIGN: In this pragmatic randomised controlled trial at five general medical or diabetes clinics in Hong Kong and Malaysia, we randomly assigned patients in a 1:1 ratio to the intervention group with Fibrosis-4 index and aspartate aminotransferase-to-platelet ratio index automatically calculated based on routine blood tests, followed by electronic reminder messages to alert clinicians of abnormal results, or the control group with usual care. The primary outcome was the proportion of patients with increased fibrosis scores who received appropriate care (referred for hepatology care or specific fibrosis assessment) within 1 year. RESULTS: Between May 2020 and Oct 2021, 1379 patients were screened, of whom 533 and 528 were assigned to the intervention and control groups, respectively. A total of 55 out of 165 (33.3%) patients with increased fibrosis scores in the intervention group received appropriate care, compared with 4 of 131 (3.1%) patients in the control group (difference 30.2% (95% CI 22.4% to 38%); p<0.001). Overall, 11 out of 533 (2.1%) patients in the intervention group and 1 out of 528 (0.2%) patients in the control group were confirmed to have advanced liver disease (difference 1.9% (95% CI 0.61% to 3.5%); p=0.006). CONCLUSION: Automated fibrosis score calculation and electronic reminders can increase referral of patients with type 2 diabetes and abnormal fibrosis scores at non-hepatology settings. TRIAL REGISTRATION NUMBER: NCT04241575.
引用
- Zhang X, Yip TC, Wong GL, et al. Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial. Gut. 2023. PMID: 37549979. doi:10.1136/gutjnl-2023-330269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。